Addressing a Public Health Need

Prior to the founding of the BBCIC there was no proactive and systematic post-approval evidence generation system in the US for purposes of monitoring biologics and biosimilars, which is an important public health need. The BBCIC meets this need with its science-driven fully transparent approach which leverages existing distributed research network resources. The BBCIC is the neutral convener to provide investigators, biopharmaceutical companies, managed care organizations (MCOs), integrated delivery networks (IDNs), pharmacy benefit managers (PBMs), physicians and patient advocates with an organized process to characterize patient populations and generate evidence for biologics including biosimilars in a manner that promotes robust and relevant scientific research and exchange and with the goal of making meaningful contributions to the scientific record.